Discovery of novel 5,5-diarylpentadienamides as orally available transient receptor potential vanilloid 1 (TRPV1) antagonists

Journal of Medicinal Chemistry

Volumn 55, Issue 7, 2012, Pages 3436-3451

  Saku, Osamu ^a   Ishida, Hiroshi ^a   Atsumi, Eri ^a   Sugimoto, Yoshiyuki ^a   Kodaira, Hiroshi ^a   Kato, Yoshimitsu ^a   Shirakura, Shiro ^a   Nakasato, Yoshisuke ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 PHENYL 3 (4 TRIFLUOROMETHYLPHENYL) 2 PROPEN 1 OL; 3 PHENYL 3 (4 TRIFLUOROMETHYLPHENYL)PROPENAL; 3 PHENYLPROPIONIC ACID ETHYL ESTER; 5 (2 DIMETHYLAMINO 6 TRIFLUOROMETHYLPYRIDIN 3 YL) 5 (4 FLUOROPHENYL) N (3 HYDROXY 2 OXO 1,2,3,4 TETRAHYDRO 5 QUINOLYL) 2,4 PENTADIENAMIDE; 5 (4 CYANOMETHOXYPHENYL) N (3 HYDROXY 2 OXO 1,2,3,4 TETRAHYDRO 5 QUINOLYL) 5 (4 TRIFLUOROMETHYLPHENYL) 2,4 PENTADIENAMIDE; 5 (4 FORMYLPHENYL) N (ISOQUINOLIN 5 YL) 5 (4 TRIFLUORO METHYLPHENYL) 2,4 PENTADIENAMIDE; 5 [4 (ISOQUINOLIN 5 YLIMINOMETHYL)PHENYL] N (ISOQUINOLIN 5 YL) 5 (4 TRIFLUOROMETHYLPHENYL) 2,4 PENTADIENAMIDE; 5 PHENYL 5 (4 TRIFLUOROMETHYLPHENYL) 2,4 PENTADIENOIC ACID; 5,5 BIS(4 TRIFLUOROMETHYLPHENYL) 2,4 PENTADIENOIC ACID; AMIDE; ETHYL 3 PHENYL 3 (4 TRIFLUOROMETHYLPHENYL)ACRYLATE; ETHYL 5 (4 FORMYLPHENYL) 5 (4 TRIFLUOROMETHYLPHENYL) 2,4 PENTADIENOATE; ETHYL 5 (4 HYDROXYPHENYL) 5 (4 TRIFLUOROMETHYL PHENYL) 2,4 PENTADIENOATE; ETHYL 5 (FURAN 2 YL) 5 (4 TRIFLUOROMETHYLPHENYL) 2,4 PENTADIENOATE; ETHYL 5 BROMO 5 (4 TRIFLUOROMETHYLPHENYL) 2,4 PENTADIENOATE; ETHYL 5 PHENYL 5 (4 TRIFLUOROMETHYLPHENYL) 2,4 PENTADIENOATE; ETHYL 5,5 BIS(4 TRIFLUOROMETHYLPHENYL) 2,4 PENTADIENOATE; ETHYL 5,5 DIBROMO 2,4 PENTADIENOATE; ETHYL IODO 3 PHENYLACRYLATE; METHYL 3 (4 TRIFLUOROMETHYLPHENYL)ACRYLATE; METHYL 5 PHENYL 5 (4 TRIFLUOROMETHYLPHENYL) 2,4 PENTADIENOATE; N (3 HYDROXY 2 OXO 1,2,3,4 TETRAHYDRO 5 QUINOLYL) 5 (4 PROPOXYPHENYL) 5 (4 TRIFLUOROMETHYLPHENYL) 2,4 PENTADIENAMIDE; N (3 HYDROXY 2 OXO 1,2,3,4 TETRAHYDRO 5 QUINOLYL) 5 [4 (OXETAN 3 YLOXY)PHENYL] 5 (4 TRIFLUOROMETHYLPHENYL) 2,4 PENTADIENAMIDE; N (ISOQUINOLIN 5 YL) 5 (4 TRIFLUOROMETHYLPHENYL) 2,4 PENTADIENAMIDE; N (ISOQUINOLIN 5 YL) 5 [4 (MORPHOLIN 4 YLMETHYL) PHENYL] 5 (4 TRIFLUOROMETHYLPHENYL) 2,4 PENTADIENAMIDE; N (ISOQUINOLIN 5 YL) 5 PHENYL 5 (4 TRIFLUOROMETHYL PHENYL) 2,4 PENTADIENAMIDE; N (ISOQUINOLIN 5 YL) 5 PHENYL 5 (4 TRIFLUOROMETHYL PHENYL) 2,4 PENTADINENAMIDE; N (ISOQUINOLIN 5 YL) 5,5 BIS(4 TRIFLUOROMETHYLPHENYL) 2,4 PENTADINENAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANILLOID RECEPTOR 1 ANTAGONIST;

ALLODYNIA; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; CHEMICAL STRUCTURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG PENETRATION; DRUG SYNTHESIS; ENANTIOSELECTIVITY; HIGH THROUGHPUT SCREENING; HYPERALGESIA; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; MAXIMUM PLASMA CONCENTRATION; NERVE INJURY; NEUROPATHIC PAIN; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; SCIATIC NERVE INJURY; THERMAL HYPERALGESIA; X RAY CRYSTALLOGRAPHY;

ALKADIENES; AMIDES; ANALGESICS; ANIMALS; BLOOD-BRAIN BARRIER; CALCIUM; CAPSAICIN; DOGS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; HAPLORHINI; HEK293 CELLS; HUMANS; HYPERALGESIA; MALE; MICROSOMES, LIVER; NEURALGIA; QUINOLONES; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRPV CATION CHANNELS;

EID: 84859805419     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300101n     Document Type: Article

References (28)

1. Caterina, M. J.; Schumaker, M. A.; Tominaga, M.; Rosen, T. A.; Levine, J. D.; Julius, D. The capsaicin receptor: a heat-activated ion channel in the pain pathway Nature 1997, 389, 816-824
2. Holzer, P. Local effector functions of capsaicin-sensitive sensory nerve endings: involvement of tachykinins, calcitonin gene-related peptide and other neuropeptides Neuroscience 1988, 24, 739-768
3. Di Marzo, V.; Blumberg, P. M.; Szallasi, A. Endovanilloid signalling in pain Curr. Opin. Neurobiol. 2002, 12, 372-379
4. Kress, M.; Zeihofer, H. U. Capsaicin, protons and heat: new excitement about nociceptors Trends Pharmacol. Sci. 1999, 20, 112-118
5. Zygmunt, P. M.; Petersson, J.; Andersson, D. A.; Chuang, H.; Sørgard, M.; Di Marzo, V.; Julius, D.; Högestätt, E. D. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide Nature 1999, 400, 452-457
6. Hwang, S. W.; Cho, H.; Kwak, J.; Lee, S.-J.; Kang, C.-J.; Jung, J.; Cho, S.; Min, K. H.; Suh, Y.-G.; Kim, D.; Oh, U. Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 6155-6160
7. Caterina, M. J.; Julius, D. The vanilloid receptor: a molecular gateway to the pain pathway Annu. Rev. Neurosci. 2001, 24, 487-517
8. Caterina, M. J.; Leffler, A.; Malmberg, A. B.; Martin, W. J.; Trafton, J.; Petersen-Zeitz, K. R.; Koltzenburg, M.; Basbaum, A. I.; Julius, D. Impaired nociception and pain sensation in mice lacking the capsaicin receptor Science 2000, 288, 306-313
9. Davis, J. B.; Gray, J.; Gunthorpe, M. J.; Hatcher, J. P.; Davey, P. T.; Overend, P.; Harries, M. H.; Latcham, J.; Clapham, C.; Atkinson, K.; Hughes, S. A.; Rance, K.; Grau, E.; Harper, A. J.; Pugh, P. L.; Rogers, D. C.; Bingham, S.; Randall, A.; Sheardown, S. A. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia Nature 2000, 405, 183-187
10. Szallasi, A.; Blumberg, P. M. Vanilloid receptors: new insights enhance potential as a therapeutic target Pain 1996, 68, 195-208
11. Pomonis, J. D.; Harrison, J. E.; Mark, L.; Bristol, D. R.; Valenzano, K. J.; Walker, K. N -(4-Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl) tetrahydropyrazine-1(2 H)-carboxamide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: II. In vivo characterization in rat models of inflammatory and neuropathic pain J. Pharmacol. Exp. Ther. 2003, 306, 387-393
12. Gavva, N. R.; Tamir, R.; Qu, Y.; Klionsky, L.; Zhang, T. J.; Immke, D.; Wang, J.; Zhu, D.; Vanderah, T. W.; Porreca, F.; Doherty, E. M.; Norman, M. H.; Wild, K. D.; Bannon, A. W.; Louis, J. C.; Treanor, J. J. AMG 9810 [(E)-3-(4-t-butylphenyl)- N -(2,3-dihydrobenzo[ b ][1,4]dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic properties J. Pharmacol. Exp. Ther. 2005, 313, 474-484
13. Gomtsyan, A.; Bayburt, E. K.; Schmidt, R. G.; Zheng, G. Z.; Perner, R. J.; Didomenico, S.; Koenig, J. R.; Turner, S.; Jinkerson, T.; Drizin, I.; Hannick, S. M.; Macri, B. S.; McDonald, H. A.; Honore, P.; Wismer, C. T.; Marsh, K. C.; Wetter, J.; Stewart, K. D.; Oie, T.; Jarvis, M. F.; Surowy, C. S.; Faltynek, C. R.; Lee, C.-H. Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain: structure-activity relationships for ureas with quinoline, isoquinoline, quinazoline, phthalazine, quinoxaline, and cinnoline moieties J. Med. Chem. 2005, 48, 744-752
14. Doherty, E. M.; Fotsch, C.; Bo, Y.; Chakrabarti, P. P.; Chen, N.; Gavva, N.; Han, N.; Kelly, M. G.; Kincaid, J.; Klionsky, L.; Liu, Q.; Ognyanov, V. I.; Tamir, R.; Wang, X.; Zhu, J.; Norman, M. H.; Treanor, J. J. S. Discovery of potent, orally available vanilloid receptor-1 antagonists. Structure-activity relationship of N -aryl cinnamides J. Med. Chem. 2005, 48, 71-90
15. Szallasi, A.; Appendino, G. Vanilloid receptor antagonists as the next generation of painkillers. Are we putting the cart before the horse? J. Med. Chem. 2004, 47, 2717-2723
16. Breitenbucher, J. G.; Chaplan, S. R.; Carruthers, N. I. The TRPV1 vanilloid receptor: a target for therapeutic intervention Annu. Rep. Med. Chem. 2005, 40, 185-198
17. Kouhen, R. E.; Surowy, C. S.; Bianchi, B. R.; Neelands, T. R.; McDonald, H. A.; Niforatos, W.; Gomtsyan, A.; Lee, C.-H.; Honore, P.; Sullivan, J. P.; Jarvis, M. F.; Faltynek, C. R. A-425619 [1-isoquinolin-5-yl-3-(4- trifluoromethyl-benzyl)-urea], a novel and selective transient receptor potential type 1 receptor antagonist, blocks channel activation by vanilloids, heat, and acid J. Pharmacol. Exp. Ther. 2005, 314, 400-409
18. Kakarala, M.; Dubey, S. K.; Tarnowski, M.; Cheng, C.; Liyanage, S.; Strawder, T.; Tazi, K.; Sen, A.; Djuric, Z.; Brenner, D. E. Ultra-low flow liquid chromatography assay with ultraviolet (UV) detection for piperine quantitation in human plasma J. Agric. Food Chem. 2010, 58, 6594-6599
19. Szallasi, A.; Cortright, D. N.; Blum, C. A.; Eid, S. R. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept Nat. Rev. Drug Discovery 2007, 6, 357-372
20. Cui, M.; Honore, P.; Zhong, C.; Gauvin, D.; Mikusa, J.; Hernandez, G.; Chandran, P.; Gomtsyan, A.; Brown, B.; Bayburt, E. K.; Marsh, K.; Bianchi, B.; McDonald, H.; Niforatos, W.; Neelands, T. R.; Moreland, R. B.; Decker, M. W.; Lee, C.-H.; Sullivan, J. P.; Faltynek, C. R. TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists J. Neurosci. 2006, 26, 9385-9393
21. McDonnell, M. E.; Zhang, S.-P.; Nasser, N.; Dubin, A. E.; Dax, S. L. 7-Hydroxynaphthalen-1-yl-urea and -amide antagonists of human vanilloid receptor 1 Bioorg. Med. Chem. Lett. 2004, 14, 531-534
22. Shen, W. A modified Suzuki reaction of 1,1-dibromo-1-alkenes Synlett 2000, 5, 737-739
23. Piers, E.; Wong, T.; Coish, P. D.; Rogers, C. A convenient procedure for the efficient preparation of alkyl (Z)-3-iodo-2-alkenoates Can. J. Chem. 1994, 72, 1816-1819
24. Bouchon, A.; Diedrichs, N.; Hermann, A.; Lustig, K.; Meier, H.; Pernerstorfer, J.; Reissmüller, E.; Mogi, M.; Fujishima, H.; Tajimi, M.; Yamamoto, N. Tetrahydro-quinolinylurea Derivatives. WO 2005/044802 A2, 2005.
25. Masubuchi, K.; Taniguchi, M.; Umeda, I.; Hattori, K.; Suda, H.; Kohchi, Y.; Isshiki, Y.; Sakai, T.; Kohchi, M.; Shirai, M.; Okabe, H.; Sudoh, M.; Yamazaki, T.; Shimma, N. Synthesis and structure-activity relationships of novel fungal chitin synthase inhibitors Bioorg. Med. Chem. Lett. 2000, 10, 1459-1462
26. Callegari, E.; Malhotra, B.; Bungay, P. J.; Webster, R.; Fenner, K. S.; Kempshall, S.; LaPerle, J. L.; Michel, M. C.; Kay, G. G. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder Br. J. Clin. Pharmacol. 2011, 72, 235-246
27. Wang, H.-L.; Katon, J.; Balan, C.; Bannon, A. W.; Bernard, C.; Doherty, E. M.; Dominguez, C.; Gavva, N. R.; Gore, V.; Ma, V.; Nishimura, N.; Surapaneni, S.; Tang, P.; Tamir, R.; Thiel, O.; Treanor, J. J.; Norman, M. H. Novel vanilloid receptor-1 antagonists: 3. The identification of a second-generation clinical candidate with improved physicochemical and pharmacokinetic properties J. Med. Chem. 2007, 50, 3528-3539
28. Fisher, K.; Fundytus, M. E.; Cahill, C. M.; Coderre, T. J. Intrathecal administration of the mGluR compound, (S)-4CPG, attenuates hyperalgesia and allodynia associated with sciatic nerve constriction injury in rats Pain 1998, 77, 59-66